Streetbeat News

IMNM

Immunome, Inc.

https://immunome.com

Industry

Biotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

In Tuesday's after-market session, several health care stocks experienced significant movements. Rezolute (RZLT) saw a 52.7% increase, Mustang Bio (MBIO) rose by 30.64%, and Qilian Intl Hldg Gr (QLI) increased by 14.77%. On the downside, Durect (DRRX) fell by 13.2%, Cingulate (CING) decreased by 10.1%, and Haemonetics (HAE) dropped by 8.79%.

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 8:31 pm

Immunome's President and CEO, Clay B Siegall, has purchased 100,000 shares of the company's stock at $13.88 per share, as per a recent SEC Form 4 filing.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:27 pm

Immunome has promoted Max Rosett to Chief Financial Officer, effective May 9. Rosett previously served as Executive Vice President, Operations, and Interim CFO since January 2024.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:05 pm

Immunome reported a significant miss in Q1 earnings and sales, with EPS at $(2.51) versus the $(0.69) estimate and sales at $1.03M against the $2.50M estimate. This represents a substantial decrease from the previous year's figures.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:18 pm

A correction has been issued stating that Immunome did not report its Q1 earnings on May 13, 2024, contrary to previous information.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:25 pm

Immunome reported Q1 earnings with losses of $(0.52) per share, surpassing the analyst consensus estimate of $(0.69) by 24.64%. However, this represents a 48.57% increase in losses compared to the same period last year, where losses were $(0.35) per share.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:24 pm

Immunome reported a Q1 EPS loss of $(0.52), surpassing the analyst consensus estimate of $(0.81) by 35.8%. However, this represents a 48.57% increase in losses compared to the same period last year, where the loss was $(0.35) per share.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:09 pm

JP Morgan analyst Brian Cheng initiates coverage on Immunome (NASDAQ:IMNM) with an Overweight rating and a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:45 pm

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 10:34 am

Immunome has filed with the SEC for a shelf offering of up to 2.2 million shares of common stock by a selling stockholder. This move allows the stockholder to sell these shares at future market prices.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.